Related Articles

Modeling the Mycobacterium tuberculosis Granuloma - the Critical Battlefield in Host Immunity and Disease.

Front Immunol. 2013;4:98

Authors: Guirado E, Schlesinger LS

Abstract
Granulomas are the hallmark of Mycobacterium tuberculosis (M.tb) infection and thus sit at the center of tuberculosis (TB) immunopathogenesis. TB can result from either early progression of a primary granuloma during the infection process or reactivation of an established granuloma in a latently infected person. Granulomas are compact, organized aggregates of immune cells consisting of blood-derived infected and uninfected macrophages, foamy macrophages, epithelioid cells (uniquely differentiated macrophages), and multinucleated giant cells (Langerhans cells) surrounded by a ring of lymphocytes. The granuloma's main function is to localize and contain M.tb while concentrating the immune response to a limited area. However, complete eradication does not occur since M.tb has its own strategies to persist within the granuloma and to reactivate and escape under certain conditions. Thus M.tb-containing granulomas represent a unique battlefield for dictating both the host immune and bacterial response. The architecture, composition, function, and maintenance of granulomas are key aspects to study since they are expected to have a profound influence on M.tb physiology in this niche. Granulomas are not only present in mycobacterial infections; they can be found in many other infectious and non-infectious diseases and play a crucial role in immunity and disease. Here we review the models currently available to study the granulomatous response to M.tb.

PMID: 23626591 [PubMed]

Related Articles

Advances in the development of new tuberculosis drugs and treatment regimens.

Nat Rev Drug Discov. 2013 May;12(5):388-404

Authors: Zumla A, Nahid P, Cole ST

Abstract
Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide. For the first time since the 1960s, new and novel drugs and regimens for all forms of TB are emerging. Such regimens are likely to utilize both repurposed drugs and new chemical entities, and several of these regimens are now progressing through clinical trials. This article covers current concepts and recent advances in TB drug discovery and development, including an update of ongoing TB treatment trials, newer clinical trial designs, TB biomarkers and adjunct host-directed therapies.

PMID: 23629506 [PubMed - in process]

Related Articles

Automatic screening for tuberculosis in chest radiographs: a survey.

Quant Imaging Med Surg. 2013 Apr;3(2):89-99

Authors: Jaeger S, Karargyris A, Candemir S, Siegelman J, Folio L, Antani S, Thoma G

Abstract
Tuberculosis (TB) is a major global health threat. An estimated one-third of the world's population has a history of TB infection, and millions of new infections are occurring every year. The advent of new powerful hardware and software techniques has triggered attempts to develop computer-aided diagnostic systems for TB detection in support of inexpensive mass screening in developing countries. In this paper, we describe the medical background of TB detection in chest X-rays and present a survey of the recent approaches using computer-aided detection. After a thorough research of the computer science literature for such systems or related methods, we were able to identify 16 papers, including our own, written between 1996 and early 2013. These papers show that TB screening is a challenging task and an open research problem. We report on the progress to date and describe experimental screening systems that have been developed.

PMID: 23630656 [PubMed - in process]